No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference.

This publication has 20 references indexed in Scilit:

• Dolutegravir and weight gain
  AIDS, 2017
• Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients
  HIV Medicine, 2016
• Switching regimens in virologically suppressed HIV‐1‐infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)‐containing regimens
  HIV Medicine, 2016
• Correction: Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study
  Antiviral Therapy, 2016
• Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study
  The Lancet HIV, 2015
• Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
  The Lancet Infectious Diseases, 2013
• In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
  Antimicrobial Agents and Chemotherapy, 2011
• Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study
  AIDS, 2010
• Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
  The Lancet, 2010
• Mortality in the Highly Active Antiretroviral Therapy Era
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2006